Finance

Lists
Why is MANE down 5.43%?
Dive Deeper
MANE:NYSE
Veradermics Inc
$108.82
-5.43%
(-6.25) 1D
$108.82
0.00% (0.00)
After hours
Closed: Oct 16, 4:00:02 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MANE...
Open
$114.19
High
$114.25
Low
$106.51
Mkt. cap
4.55B
Avg. vol.
843.33K
Volume
672.94K
52-wk high
$136.72
52-wk low
$32.00
EPS
-$3.35
No. of employees
37
Open
$114.19
High
$114.25
Low
$106.51
Mkt. cap
4.55B
Avg. vol.
843.33K
Volume
672.94K
52-wk high
$136.72
52-wk low
$32.00
EPS
-$3.35
No. of employees
37
News stories
From web sources and news partners
About Veradermics Inc
CEO-
Employees37
Founded2019
HeadquartersNew Haven, Connecticut, United States
SectorPharmaceutical industry
Websiteveradermics.com
Analyst ratings
Based on 4 analysts giving stock ratings to MANE in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for MANE in the last 3 months.
Highest
Current $108.82
$182.00 (+67.25%)
Average
$169.00 (+55.30%)
Lowest
$160.00 (+47.03%)
Analyst
Recommendation
Action
Price target
Projected
Date
Geoff Meacham
Citi
Buy
Maintained
$160.00
+47%
10/15/2026
Roger Song
Jefferies
Buy
Maintained
$182.00
+67.2%
09/08/2026
Unknown Analyst
Jefferies
Buy
Maintained
$182.00
+67.2%
09/08/2026
Serge Belanger
Needham
Buy
Maintained
$164.00
+50.7%
08/12/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
$170.00
+56.2%
08/11/2026
Mayank Mamtani
B. Riley Securities
Buy
Initiated
$170.00
+56.2%
07/15/2026
Marc Goodman
Leerink Partners
Buy
Initiated
$75.00
-31.1%
03/02/2026
Prakhar Agrawal
Cantor Fitzgerald
Buy
Initiated
-
-
03/01/2026
Last report
Aug 11, 2026
Fiscal period
Q2 2026
-$0.58 / -$0.64
+9.56%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Jun 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
14.33M
18.19M
20.92M
18.61M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.74M
4.82M
8.94M
10.95M
Operating expense
16.07M
23.01M
29.86M
29.55M
Total operating expenses
16.07M
23.01M
29.86M
29.55M
Operating income
-16.07M
-23.01M
-29.86M
-29.55M
Other non operating income
325.00K
258.00K
149.00K
1.21M
EBT including unusual items
-15.64M
-21.85M
-27.23M
-23.50M
EBT excluding unusual items
-15.64M
-21.85M
-27.23M
-23.50M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-15.64M
-21.85M
-27.23M
-23.50M
Net profit margin
-
-
-
-
Earnings per share
-
-104.54
-1.32
-0.58
Interest and investment income
103.00K
906.00K
2.48M
4.84M
Interest expense
-
-
-
-
Net interest expenses
103.00K
906.00K
2.48M
4.84M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps